Abstract
Very few drugs had a history similar to that of thalidomide (α-N-[phthalimido] gluramide). First introduced in the late 1950s in Germany, in 1961 thalidomide was withdrawn due to its teratogenic effects. More than three decades after, it is attracting growing interest because of its reported immunomodulatory and anti-inflammatory properties. The discovery that thalidomide inhibits angiogenesis led to preclinical and clinical trials as an anticancer agent in the treatment of solid tumours and haematological malignancies, as summarized in this review article. More recently, structural analogues of thalidomide have been synthesized in order to explore potential molecular targets of thalidomide, as well as to identify new agents with improved therapeutic efficacy.
Original language | English |
---|---|
Pages (from-to) | 1525-1531 |
Number of pages | 7 |
Journal | Leukemia |
Volume | 19 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sep 2005 |
Keywords
- Angiogenesis
- Antiangiogenesis
- Haematological malignancies
- Thalidomide
ASJC Scopus subject areas
- Hematology
- Cancer Research